Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study

Huang He, Qingqing Cai, Yi Xia, Yirong Jiang, Zhao Wang, Yu Wang, Xiaojie Fang, Lulu Zhang, Jiahao Tian

Blood (2025) 146 (Supplement 1): 5363.

https://doi.org/10.1182/blood-2025-5363

Published: 2025

Journal Articles

Lipid metabolic reprogramming mediated by YTHDF3 deficiency underlies immunotherapy resistance in extranodal NK/T-cell lymphoma

Jinni Wang, Qingqing Cai, Wenlong Zhong, Yuchen Zhang, Danling Dai, Yi Cao, Shuai Liang, Jun Cai

Blood (2025) 146 (Supplement 1): 5335.

https://doi.org/10.1182/blood-2025-5335

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Blood (2025) 146 (Supplement 1): 3587.

https://doi.org/10.1182/blood-2025-3587

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Blood (2025) 146 (Supplement 1): 886.

https://doi.org/10.1182/blood-2025-886

Published: 2025

Journal Articles

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Blood (2025) 146 (Supplement 1): 475.

https://doi.org/10.1182/blood-2025-475

Published: 2025

Journal Articles

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Blood (2025) 146 (Supplement 1): 1824.

https://doi.org/10.1182/blood-2025-1824

Published: 2025

Journal Articles

Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed/refractory classic Hodgkin lymphoma achieving complete remission

Panpan LIU, Caiyun Wang, Peng SUN, Hang Yang, Mengqiu Wu, Man Nie, Yu Wang, Qingqing Cai, Yi Xia, Huang He, Huiqiang Huang, Zhiming Li

Blood (2025) 146 (Supplement 1): 5397.

https://doi.org/10.1182/blood-2025-5397

Published: 2025

Journal Articles

Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial

Qingqing Cai, Yi Xia, Qihua Zou, Jianbo Liu, Zijian Li, Shenrui Bai, Runhui Zheng, Shuling Zhang, Bing BAI, Xiaojie Fang, Xiaoxiao Wang, Man Nie, Hang Yang

Blood (2025) 146 (Supplement 1): 1906.

https://doi.org/10.1182/blood-2025-1906

Published: 2025

Journal Articles

Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial

Qingqing Cai, Yi Xia, Shenrui Bai, Tao Zhan, Qinghua Lan, Jianbo Liu, Zi-Jian Li, Qingfang Zeng, Runhui Zheng, Shuling Zhang, Qihua Zou, Bing BAI, Xiaojie Fang, Xiaoxiao Wang, Man Nie, Hang Yang

Blood (2025) 146 (Supplement 1): 3690.

https://doi.org/10.1182/blood-2025-3690

Published: 2025

Journal Articles

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Qingqing Cai, Yi Cao, Danling Dai, Jinni Wang, Yuchen Zhang, Jie Xiong, Huiqiang Huang, Gao Yan, Yi Xia, Fang Liu, Xinna Gao, Shenrui Bai, Qihua Zou, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 3527.

https://doi.org/10.1182/blood-2025-3527

Published: 2025

Journal Articles

Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study

Yi Xia, Qingqing Cai, Dongyu Zhuang, Man Nie, Hang Yang, Honglian Liu, Yirong Jiang, Shaojiang Yang

Blood (2025) 146 (Supplement 1): 7202.

https://doi.org/10.1182/blood-2025-7202

Published: 2025

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

Yuqin Song, Ye Guo, Qingqing Cai, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Lanfang Li, Yanyan Liu, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Andrew Chow, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 5372.

https://doi.org/10.1182/blood-2025-5372

Published: 2025

Journal Articles

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Blood (2025) 146 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2025-3896

Published: 2025

Journal Articles

Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study

Yuchen Zhang, Qingqing Cai, Yongping Song, Yexiong Li, Shunan Qi, Yi Xia, Shenrui Bai, Jun Cai, Bing BAI, Xiaojie Fang, Man Nie, Yi Cao

Blood (2025) 146 (Supplement 1): 3643.

https://doi.org/10.1182/blood-2025-3643

Published: 2025

Journal Articles

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

Yuqin Song, Qingqing Cai, Ye Guo, Haisheng Liu, Mingxia Wang, Wenrong Huang, Mingzhi Zhang, Yanyan Liu, Lanfang Li, Yuerong Shuang, Zengjun Li, Cuizhen Niu, Lin-Chi Chen, Jingxia Chen, Yan Xie

Blood (2025) 146 (Supplement 1): 3740.

https://doi.org/10.1182/blood-2025-3740

Published: 2025

Journal Articles

TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study

Qingqing Cai, Yi Xia, Xiaojie Fang, Man Nie, Qihua Zou, Jun Cai, Yuchen Zhang, Qiuyi Yang, Dawei Ding, Wen Wang, Xunqiang Wang

Blood (2024) 144 (Supplement 1): 3047.

https://doi.org/10.1182/blood-2024-203156

Published: 2024

Journal Articles

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Qingqing Cai, Yi Xia, Huiqiang Huang, Ying Zhao, Fan Yang, Wenning Xu, Hongyan Tong, Chunmei Yang, Xiaojie Fang, Man Nie, Yu Fang, Gao Yan, Xuanye Zhang, Rong Tao, Xiuhua Sun, Xueyi Pan, Tao Wu, Yuchen Zhang, Jun Cai

Blood (2024) 144 (Supplement 1): 6407.

https://doi.org/10.1182/blood-2024-206564

Published: 2024

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

Preliminary Results from a Phase II Study of Chidamide in Combination with CHOP in Previously Untreated Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype (SWIFT study)

Qingqing Cai, Yi Xia, Dongfeng Zeng, Xi Li, Xiaojie Fang, Man Nie, Xiaopeng Tian, Lirong Li, Yingxian Liu

Blood (2024) 144 (Supplement 1): 7779.

https://doi.org/10.1182/blood-2024-206953

Published: 2024

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study

Lipid metabolic reprogramming mediated by YTHDF3 deficiency underlies immunotherapy resistance in extranodal NK/T-cell lymphoma

Efficacy and safety of rocbrutinib, a highly selective 4th-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory Mantle Cell Lymphoma (R/R MCL): Updated results from the phase 1 study

Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial

Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma：topline efficacy and safety results from the randomized phase 3 DEB study

Preliminary efficacy and safety of TT-01488, a novel, non-covalent, reversible BTK inhibitor, in patients with relapsed/refractory mantle cell lymphoma

Comparable survival with transplant-free approach versus autologous stem cell transplantation in adult relapsed/refractory classic Hodgkin lymphoma achieving complete remission

Preliminary results of first-line selinexor plus R-CHOP in TP53-mutated diffuse large B-cell lymphoma (Smart trial): A single-arm, phase II trial

Preliminary result of first-line orelabrutinib plus R-CHOP in CD5-positive diffuse large B-cell lymphoma (Rocket trial): A single-arm, phase II trial

Single-cell profiling of natural killer T-cell lymphoma reveals stratified immune features and therapeutic strategies

Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory follicular lymphoma

Efficacy and safety of rocbrutinib, a highly selective 4th-generation BTK inhibitor, in Chinese patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Treatment patterns and survival outcomes after immunotherapy failure in patients with NK/T cell lymphoma: A multicenter retrospective study

Phase 1 study of MK-1045, a novel CD19xCD3 T-cell engager, in participants with relapsed or refractory diffuse large B-cell lymphoma

TQB2223 in Combination with Penpulimab in Patients with Relapsed or Refractory Lymphoma: Primary Analysis of an Open-Label Phase I Study

Linperlisib in Combination with CHOP for Newly-Diagnosed Peripheral T-Cell Lymphoma: Preliminary Results from the Phase 1b/2 Linch Study

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Preliminary Results from a Phase II Study of Chidamide in Combination with CHOP in Previously Untreated Peripheral T-Cell Lymphoma with T Follicular Helper Phenotype (SWIFT study)

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only